

lutetium solution for injection/infusion (^{177}Lu) vipivotide tetraxetan (Pluvicto[®])

Novartis Pharmaceuticals UK Ltd

10 July 2026

ADVICE: in the absence of a submission from the holder of the marketing authorisation:

lutetium (^{177}Lu) vipivotide tetraxetan (Pluvicto[®]) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on or after treatment with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium